The director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center spoke on what he is looking forward to at the 2021 International Congress on the Future of Neurology.
“There are many different topics that we’re going to cover on the future of neurology, and it’s important to remember that neurology has entered, and is expanding into, a golden era of treatment options.”
With the third annual International Congress on the Future of Neurology (IFN) coming up on September 17-18, in New York City, one of the chairs of the meeting, Fred Lublin, MD, Saunders Family professor of neurology, and director, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, spoke with NeurologyLive on the topics to be discussed within all areas of neurology, including his specialty, multiple sclerosis (MS).
Lublin will be moderating the MS portion of the conference on Saturday, September 18, where experts will discuss newer MS therapeutics, gaps in care of relapsing-remitting and progressive MS, and symptomatic therapies. He noted particular excitement for the Medical Crossfire debate, where he and panelists Patricia Coyle, MD, director, MS Comprehensive Care Center, Stony Brook Neurosciences Institute; and Stephen Krieger, MD, professor of neurology, , Corinne Goldsmith Dickinson Center for MS, Mount Sinai Medical Center, will discuss starting MS therapy with only highly active agents versus starting with the full array of agents.
IFN 2021 will discuss the most recent advancements in neurology across different lines of care, and Lublin noted that the program would be beneficial for clinicians, practitioners, residents, and fellows, especially those anticipating taking their neurology boards. Attendees can opt to see discussions live at the InterContinental New York Barclay, or tune in virtually, thanks to the event’s hybrid, interactive design.